Our common stock trades on the NASDAQ under the symbol “ANIP.”
June 19, 2013
ANI Pharmaceuticals’ US headquarters is located at:
210 Main Street West
Baudette, MN 56623
Phone: 800-434-1121
FAX: 218-634-3540
Email: info@anipharmaceuticals.com
ANI Pharmaceuticals’ Canadian office is located at:
400 Iroquois Shore Road
Oakville, ON L6H 1M5
Phone: 905-337-4500
Fax: 905-337-3539
Email: info@anipharmaceuticals.com
ANI Pharmaceuticals, Inc., and its consolidated subsidiaries, ANIP Acquisition Company and ANI Pharmaceuticals Canada Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our strategy is to use our assets to develop, acquire, manufacture, and market branded and generic specialty prescription pharmaceuticals. By executing this strategy, we believe we will be able to continue to grow our business, expand and diversify our product portfolio, and create long-term value for our investors. For more information, visit www.anipharmaceuticals.com.
On June 19, 2013, pursuant to a merger agreement dated as of April 12, 2013, ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. ("ANIP") became a wholly-owned subsidiary of BioSante Pharmaceuticals, Inc. (“BioSante”) in an all-stock, tax-free reorganization (the "Merger"). The Merger was accounted for as a reverse acquisition, pursuant to which ANIP was considered the acquiring entity for accounting purposes. Since the Merger, we have been operating under the leadership of the ANIP management team and ANIP's historical results of operations have replaced BioSante's historical results of operations for all periods prior to the Merger. The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger. In July 2013, we changed our name from “BioSante Pharmaceuticals, Inc.” to “ANI Pharmaceuticals, Inc.”
Immediately prior to completion of the Merger, the Board of Directors authorized, declared and effected a distribution of contingent value rights (“CVRs”) to holders of record of Biosante Common Stock outstanding immediately prior to completion of the Merger at a rate of one CVR per one share of Common Stock. The CVRs represent payment rights arising from a future sale, transfer, license or similar transaction(s) involving the Company’s LibiGel® (female testosterone gel), including a royalty on sales of LibiGel® if the combined company launches the product on its own and if less than $2.5 million is spent on further product development before launch.
Iselin, New Jersey
No.
1 State Street, 30th Floor
New York, New York 10004-1561
Phone: 212-509-4000
Email: cstmail@continentalstock.com
Questions regarding stock transfer requirements, lost certificates and change of address should be directed to the transfer agent as listed.
No, ANI Pharmaceuticals does not offer a direct stock purchase plan. Shares can be purchased through a stockbroker of your choice.
December 31
ANI Pharmaceuticals’ Investor Relations department is happy to answer any shareholder questions at IR@anipharmaceuticals.com.
Requests for filings with the U.S Securities and Exchange Commission should be directed to Investor Relations at IR@anipharmaceuticals.com. SEC filings are also available on our website at www.anipharmaceuticals.com.
